指南与共识前列腺癌

晚期前列腺癌患者的管理:2024年晚期前列腺癌共识会议(APCCC)报告

Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC).
指南 / 共识 · Eur Urol · 2024-10-11

2024年晚期前列腺癌共识会议(APCCC)采用改良德尔菲法,由120位国际前列腺癌专家制定183个选择题,会前通过在线调查收集投票。共识预先定义为≥75%同意,强共识为≥90%同意。投票结果可帮助医生和患者在高级别证据匮乏或矛盾的争议领域进行临床决策,并帮助资助者和政策制定者确定未来研究重点。

要点

  • 共识预先定义为≥75%同意,强共识为≥90%同意。
  • 投票结果不包含正式文献综述或Meta分析。
  • 诊断和治疗决策应始终基于患者和癌症特征个体化,并结合当前和新兴临床证据、指南及后勤经济因素。

核心结论

  • 投票结果可帮助医生和患者在高级别证据匮乏或矛盾的争议领域进行临床决策。
  • 投票结果可帮助资助者和政策制定者确定未来研究重点。
  • 诊断和治疗决策应始终基于患者和癌症特征个体化,并结合当前和新兴临床证据、指南及后勤经济因素。
  • 始终强烈鼓励参加临床试验。
  • APCCC 2024再次确定了需在专门设计的试验中评估的重要空白(无共识领域)。

研究设计与样本

  • 会前由120位国际前列腺癌专家组成的小组使用改良德尔菲法制定了183个关于八个不同主题的多选题共识问题。
  • 会前通过基于网络的调查将这些问卷发放给投票小组成员(「专家组成员」)。

主要发现

  • 投票结果显示不同程度的共识,如本文所讨论并在补充材料中详述。
  • 这些发现不包含正式文献综述或Meta分析。

关键数值与推荐

  • 共识预先定义为≥75%同意,强共识定义为≥90%同意。

临床怎么用

  • 诊断和治疗决策应始终基于患者和癌症特征个体化,并应结合当前和新兴临床证据、指南及后勤经济因素。
  • 始终强烈鼓励参加临床试验。

局限性

  • 这些发现不包含正式文献综述或Meta分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Innovations have improved outcomes in advanced prostate cancer (PC). Nonetheless, we continue to lack high-level evidence on a variety of topics that greatly impact daily practice. The 2024 Advanced Prostate Cancer Consensus Conference (APCCC) surveyed experts on key questions in clinical management in order to supplement evidence-based guidelines. Here we present voting results for questions from APCCC 2024. METHODS: Before the conference, a panel of 120 international PC experts used a modified Delphi process to develop 183 multiple-choice consensus questions on eight different topics. Before the conference, these questions were administered via a web-based survey to the voting panel members ("panellists"). KEY FINDINGS AND LIMITATIONS: Consensus was a priori defined as ≥75% agreement, with strong consensus defined as ≥90% agreement. The voting results show varying degrees of consensus, as discussed in this article and detailed in the Supplementary material. These findings do not include a formal literature review or meta-analysis. CONCLUSIONS AND CLINICAL IMPLICATIONS: The voting results can help physicians and patients navigate controversial areas of clinical management for which high-level evidence is scant or conflicting. The findings can also help funders and policymakers in prioritising areas for future research. Diagnostic and treatment decisions should always be individualised on the basis of patient and cancer characteristics, and should incorporate current and emerging clinical evidence, guidelines, and logistic and economic factors. Enrolment in clinical trials is always strongly encouraged. Importantly, APCCC 2024 once again identified important gaps (areas of nonconsensus) that merit evaluation in specifically designed trials.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Gillessen S, Turco F, Davis ID, et al. Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC). Eur Urol. 2024. PMID: 39394013. doi:10.1016/j.eururo.2024.09.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。